Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 8, 2012, Pages 941-947

  Gisbert, J P ^a,b   Castro Fernandez, M ^b,c   Perez Aisa, A ^d   Cosme, A ^b,e   Molina Infante, J ^f   Rodrigo, L ^g   Modolell, I ^h   Cabriada, J L ⁱ   Gisbert, J L ^a   Lamas, E ^b,c   Marcos, E ^a   Calvet, X ^b,j  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d Gastroenterology Department   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f San Pedro de Alcántara Hospital   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h Gastroenterology Department   (Spain)

ⁱ HOSPITAL DE GALDAKAO   (Spain)

^j HOSPITAL DE SABADELL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CARBON 13; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; APHTHOUS STOMATITIS; ARTICLE; ASTHENIA; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; TASTE DISORDER; THROMBOCYTOPENIA; UREA BREATH TEST;

ADULT; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PEPTIC ULCER; PROSPECTIVE STUDIES; QUESTIONNAIRES; RIFABUTIN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84858800451     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05053.x     Document Type: Article

References (41)

1. McColl KE,. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-604.
2. Gisbert JP, Pajares JM,. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
3. Malfertheiner P, Megraud F, O'Morain C, et al,. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
4. Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S,. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
5. Gisbert JP,. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med 2011; 50: 2717.
6. Gisbert JP, Morena F,. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44.
7. Gisbert JP, Pajares JM,. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005; 10: 363-72.
8. Gisbert JP, Calvet X,. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-21.
9. Piccolomini R, Di Bonaventura G, Picciani C, Laterza F, Vecchiet J, Neri M,. In vitro activity of clarithromycin against intracellular Helicobacter pylori. Antimicrob Agents Chemother 2001; 45: 1568-71.
10. Akada JK, Shirai M, Fujii K, Okita K, Nakazawa T,. In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob Agents Chemother 1999; 43: 1072-6.
11. Heep M, Beck D, Bayerdorffer E, Lehn N,. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497-9.
12. Brogden RN, Rifabutin FA,. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 983-1009.
13. Rossi R, Jabes D, Della Bruna C,. In vitro activity of rifabutin, a potential antibiotic in the therapy of Helicobacter pylori. In: Abstract Book of the 6th International Congress ofr Infectious Diseases (ICID). Prague, Czech Republic, 1994; 69: 1994.
14. Kunin CM,. Antimicrobial activity of rifabutin. Clin Infect Dis. 1996; 22 (Suppl. 1): S3-13.
15. Megraud F,. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64: 1893-904.
16. Gisbert JP, Badia X, Roset M, Pajares JM,. The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice. Helicobacter 2004; 9: 28-38.
17. Gisbert JP, Castro-Fernandez M, Bermejo F, et al,. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101: 243-7.
18. Bock H, Koop H, Lehn N, Heep M,. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000; 31: 222-5.
19. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A,. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001; 15: 143.
20. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM,. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-54.
21. Miehlke S, Schneider-Brachert W, Kirsch C, et al,. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2008; 13: 69-74.
22. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A,. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-6.
23. Van der Poorten D, Katelaris PH,. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007; 12: 1537-42.
24. van Zanten SV, Desai S, Best L, et al,. Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. Can J Gastroenterol 2010; 24: 303-6.
25. De Francesco V, Giorgio F, Hassan C, et al,. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19: 409-14.
26. Pilotto A, Franceschi M, Rassu M, Furlan F, Scagnelli M,. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000; 95: 833-4.
27. Beales IL,. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol 2001; 1: 7.
28. Wong WM, Gu Q, Lam SK, et al,. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553-60.
29. Toracchio S, Capodicasa S, Soraja DB, Cellini L, Marzio L,. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33-8.
30. Borody TJ, Pang G, Wettstein AR, et al,. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 481-8.
31. Miehlke S, Hansky K, Schneider-Brachert W, et al,. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24: 395-403.
32. Castro-Fernandez M, Lamas E, Perez-Pastor A, et al,. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Rev Esp Enferm Dig 2009; 101: 395-8.
33. Perri F, Festa V, Clemente R, et al,. Randomized study of two "rescue" therapies for Helicobacter pylori- infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62.
34. Navarro-Jarabo JM, Fernandez N, Sousa FL, et al,. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection. BMC Gastroenterol 2007; 7: 31.
35. Qasim A, Sebastian S, Thornton O, et al,. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-6.
36. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM,. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469-74.
37. Apseloff G, Fluids G, LaBoy-Goral L, Kraut E, Vincent J,. Severe neutropenia caused by recommended prophylactic doses of rifabutin. Lancet 1996; 348: 685.
38. Griffith DE, Brown BA, Girard WM, Wallace RJ, Jr,. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995; 21: 594-8.
39. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM,. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 90-4.
40. Burman W, Benator D, Vernon A, et al,. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-6.
41. Li J, Munsiff SS, Driver CR, Sackoff J,. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41: 83-91.